Abbott’s Portico with Flexnav Tavr System Receives the US FDA’s Approval for the Treatment of Aortic Valve Disease
Abbott’s Portico with Flexnav Tavr System Receives the US FDA’s Approval for the Treatment of Aortic Valve Disease
Shots:
- The US FDA has approved Abbott’s Portico with FlexNav TAVR system to treat patients with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. The system provides a safe & effective treatment option
- Abbott’s Portico is a self-expanding TAVR valve with an intra-annular leaflet that is designed to provide optimal blood flow when placed inside a patient’s natural valve
- Portico device is implanted using Abbott’s FlexNav delivery system to accommodate different patient anatomies, small vessels, flexibility, tracking & precision of valve placement. Abbott offers a robust portfolio of structural heart solutions in the US including minimally invasive therapies
Click here to read full press release/ article | Ref: Abbott | Image: Media Post